This is an old revision of the document!
Dr. Scott Gottlieb Was A Pfizer Board Member, As Of November 15, 2021. According to their Pfizer board member page, Dr. Scott Gottlieb is a member of Pfizer’s board of directors.
Gottlieb Was The Commissioner Of The Food And Drug Administration (FDA) Under The Trump Administration. “President Donald Trump’s pick to lead the Food and Drug Administration, Scott Gottlieb, is a physician, a cancer survivor, a venture capitalist and a government insider who has long said he wants to tear down the wall of FDA regulations he believes is holding back innovation.’” [CNN, 4/4/17]
Gottlieb Served As FDA Commissioner From 2017 To 2019. [Pfizer, accessed 11/19/21]
Gottlieb Was A Senior Fellow At The American Enterprise Institute (AEI), As Of November 15, 2021. “Scott Gottlieb, MD, is a senior fellow at the American Enterprise Institute (AEI). He returned to AEI in 2019 after serving as the 23rd commissioner of the Food and Drug Administration (FDA). At AEI, he continues his work on improving public health through entrepreneurship and medical innovation and on expanding regulatory approaches to maintain patient and physician autonomy. Dr. Gottlieb is also a special partner with the venture capital firm New Enterprise Associates and serves on the boards of Pfizer, Illumina, and Tempus.” American Enterprise Institute
AEI Is A Conservative Think Tank. “The Prince-ton basketball player was a key figure on welfare policy for both New York state and NYC, where he became known nationally as a vocal proponent of work requirements and ran the city’s mammoth Department of Human Resources. This month, he takes over as head of the American Enterprise Institute, the august conservative think tank on Massachusetts Avenue.” [Washington, 7/8/19]
Gottlieb Was The Former Deputy Commissioner Of The FDA Under President George W. Bush. “Scott Gottlieb, President Trump’s choice for head of the Food and Drug Administration, was confirmed by the Senate on Tuesday in a 57 to 42 vote. The former deputy commissioner of the FDA under George W. Bush will come to the job with strong views about what FDA reform might look like — unlike many of Trump’s other nominees.”[Vox, 5/10/17]
Gottlieb Had An “'Unprecedented'” Amount Of Conflicts Of Interest Tied To The Pharmaceutical Industry And Had Been Paid “Millions Of Dollars” By Industry Interests He Would Oversee At The FDA. Experts Warned Of Gottlieb’s “Myriad Conflicts Of Interest” Due To The “Millions Of Dollars” He Had Been Paid By Industry In The Years Before Trump Nominated Him To Lead The FDA. “President Trump has repeatedly slammed pharmaceutical companies for 'getting away with murder' on soaring drug prices, but he and his nominee to head the Food and Drug Administration have pledged to ease industry regulations and speed approvals for medicines and other consumer products. The nominee, Dr. Scott Gottlieb, has spent the bulk of his career working in the drug and health care industry, which experts say raises the potential for myriad conflicts of interest. If confirmed to head the F.D.A., he would wield considerable power over companies and investment firms that have paid him millions of dollars over the years.” [New York Times, 3/19/17]
2013-2015: Gottlieb Was Paid $413,700 In Consulting Fees From Pharmaceutical Companies That Were All “Likely To Have Regulatory Business With The FDA” During Gottlieb's Tenure. “From 2013 through 2015 — the extent of a database maintained by the Department of Health and Human Services — Gottlieb received some $413,700 received from drug companies for consulting, speaking or other services. In 2015 alone, he collected $199,951 from eight drug companies, including GlaxoSmithKline, Squibb, Pfizer and Valeant. All are likely to have regulatory business with the FDA in coming years.” Los Angeles Times, 3/16/17
2005- After Taking His Position At The FDA, Gottlieb Had To Recuse Himself From Participating In Matters Involving Nine Drug Companies. “This wouldn’t be the first time that Gottlieb’s conflicts of interest raised eyebrows. Upon taking up his FDA post in 2005, he had to recuse himself for up to a year from participating in matters involving nine drug companies, including Eli Lilly, Roche, Procter & Gamble and Sanofi-Aventis.” Los Angeles Times, 3/16/17
Public Citizen's Health Research Group’s Michael Carome: “Gottlieb Is 'Entangled In An Unprecedented Web Of Big Pharma Ties.'” “’Gottlieb is 'entangled in an unprecedented web of Big Pharmaties,’ Michael Carome, director of the Health Research Group at the advocacy organization Public Citizen, told me.” [Los Angeles Times, 3/16/17]